Next Article in Journal
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma
Next Article in Special Issue
Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review
Previous Article in Journal
Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients
Previous Article in Special Issue
A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer

Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer

Department of Surgery, University Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy
Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy
Department of Chemistry, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
Department of Radiology and Precision Health Program, Michigan State University, East Lansing, MI 48824, USA
Author to whom correspondence should be addressed.
Cancers 2021, 13(1), 93;
Received: 27 October 2020 / Revised: 4 December 2020 / Accepted: 24 December 2020 / Published: 30 December 2020
(This article belongs to the Special Issue New Insights into Pancreatic Cancer)
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage and is burdened by poor prognosis. Its early diagnosis is rare because the disease is frequently asymptomatic for a long time. Our research aims to identify a useful and simple diagnostic tool for early PDAC detection. The combination of user-friendly, nanotechnology-based tools and standard blood tests showed high accuracy in discriminating PDAC patients from healthy subjects. If confirmed in large-cohort studies, these findings could represent an innovative and non-invasive method with a potential impact in clinical practice in early detection of PDAC.
Simultaneous detection of multiple analytes from a single biological sample is gaining more attention in the development of more reliable and point-of-care diagnostic devices. We developed a multiplexed strategy that combined outcomes of clinical biomarkers with analysis of the protein corona that forms around graphene oxide sheets upon exposure to patient’s plasma. As a paradigmatic case study, we selected pancreatic ductal adenocarcinoma (PDAC), mainly because of the absence of effective detection strategies that resulted in an extremely low five-year survival rate after diagnosis (<10%). Association of protein corona analysis and haemoglobin levels discriminated PDAC patients from healthy volunteers in up to 90% of cases. If further confirmed in larger-cohort studies, this approach may be used in the detection of PDAC. View Full-Text
Keywords: pancreatic cancer; graphene oxide; early detection pancreatic cancer; graphene oxide; early detection
Show Figures

Figure 1

MDPI and ACS Style

Caputo, D.; Digiacomo, L.; Cascone, C.; Pozzi, D.; Palchetti, S.; Di Santo, R.; Quagliarini, E.; Coppola, R.; Mahmoudi, M.; Caracciolo, G. Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer. Cancers 2021, 13, 93.

AMA Style

Caputo D, Digiacomo L, Cascone C, Pozzi D, Palchetti S, Di Santo R, Quagliarini E, Coppola R, Mahmoudi M, Caracciolo G. Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer. Cancers. 2021; 13(1):93.

Chicago/Turabian Style

Caputo, Damiano, Luca Digiacomo, Chiara Cascone, Daniela Pozzi, Sara Palchetti, Riccardo Di Santo, Erica Quagliarini, Roberto Coppola, Morteza Mahmoudi, and Giulio Caracciolo. 2021. "Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer" Cancers 13, no. 1: 93.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop